ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute's Vanguard Study.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Vanguard Study: Assessing feasibility of conducting randomized trials of novel multi-cancer detection tests.Contemporary clinical trials · 2026Article
- Innovative approaches for lung cancer screening and interception.Nature reviews. Clinical oncology · 2026Review
- Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102).Journal of the National Cancer Institute · 2026Observational
- Early Cancer Detection: What's Going on and What's Next.MedComm · 2026Review
- Early detection of multiple cancers: the era of methylation-based liquid biopsy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Cancer Screening Research Network is a new clinical trials network funded by the NCI. The first Cancer Screening Research Network study, the Vanguard Study (VS), will assess the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials.
methodsThis article describes the framework NCI developed to engage MCD assay developers, evaluate emerging technologies using biobank reference sets, and select fit-for-purpose MCD assays for inclusion in the VS.
resultsNCI evaluated 23 technologically diverse MCD assays, all utilizing machine learning and artificial intelligence components. Nine assays underwent blinded performance evaluations using specimens from three biobanks. Assay developers were provided with independent assessments of their assays, which enabled them to make further assay refinements to enhance performance. The assay selection process resulted in participation by two assay companies in the VS.
conclusionsNCI created a fair and transparent process to streamline the evaluation of assay performance and to select promising assays for clinical research and public health initiatives. IMPACT: Significant resources are required for large-scale cancer screening trials; therefore, promising technologies must be prioritized for inclusion in a definitive trial. NCI's assay selection framework can be used and repurposed by other networks and institutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.